170 related articles for article (PubMed ID: 32541460)
21. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
22. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
[TBL] [Abstract][Full Text] [Related]
23. Maintenance Therapy in HER2-Negative Metastatic Breast Cancer: A New Approach for an Old Concept.
Ciruelos E; Pérez-García JM; Gavilá J; Rodríguez A; de la Haba-Rodriguez J
Clin Drug Investig; 2019 Jul; 39(7):595-606. PubMed ID: 31054086
[TBL] [Abstract][Full Text] [Related]
24. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
25. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
26. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
[TBL] [Abstract][Full Text] [Related]
27. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract][Full Text] [Related]
28. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
30. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.
Patterson-Lomba O; Dalal AA; Ayyagari R; Liu O; Dervishi E; Platt E; Chandiwana D; O'Shaughnessy JA
Breast J; 2019 Sep; 25(5):880-888. PubMed ID: 31290203
[TBL] [Abstract][Full Text] [Related]
31. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK; Lee SH; Kim YJ; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Ahn JS; Im YH; Yu JH; Park YH
BMC Cancer; 2019 Jan; 19(1):84. PubMed ID: 30654765
[TBL] [Abstract][Full Text] [Related]
32. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
Davie A; Carter GC; Rider A; Pike J; Lewis K; Bailey A; Price GL; Ringeisen F; Pivot X
BMC Cancer; 2020 Sep; 20(1):855. PubMed ID: 32894087
[TBL] [Abstract][Full Text] [Related]
33. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
34. Patient Case Lessons: Endocrine Management of Advanced Breast Cancer.
Robert NJ; Denduluri N
Clin Breast Cancer; 2018 Jun; 18(3):192-204. PubMed ID: 28666813
[TBL] [Abstract][Full Text] [Related]
35. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
Glück S; Arteaga CL; Osborne CK
Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
[TBL] [Abstract][Full Text] [Related]
36. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
37. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of receptor conversion in metastatic breast cancer: Case report.
Silva DJ; Miranda G; Mesquita A
Medicine (Baltimore); 2022 Jun; 101(23):e29136. PubMed ID: 35687769
[TBL] [Abstract][Full Text] [Related]
40. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A; Biganzoli L; Bordonaro R; Cinieri S; Conte P; Laurentis M; Mastro LD; Gori S; Lauria R; Marchetti P; Michelotti A; Montemurro F; Naso G; Pronzato P; Puglisi F; Tondini CA
Future Oncol; 2020 Feb; 16(5):129-145. PubMed ID: 31849236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
